Aerovate Therapeutics (NASDAQ:JBIO) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Aerovate Therapeutics (NASDAQ:JBIOFree Report) to a hold rating in a research report sent to investors on Saturday.

Aerovate Therapeutics Stock Performance

Shares of NASDAQ JBIO opened at $6.76 on Friday. Aerovate Therapeutics has a twelve month low of $6.57 and a twelve month high of $884.97. The company has a market cap of $5.69 million, a price-to-earnings ratio of -0.11 and a beta of 0.93.

Aerovate Therapeutics Company Profile

(Get Free Report)

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.

Recommended Stories

Receive News & Ratings for Aerovate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerovate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.